Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

GlycoMimetics Inc

GLYC
Current price
1.72 USD +0.09 USD (+5.52%)
Last closed 1.64 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 110 756 480 USD
Yield for 12 month -23.56 %
Week
Month
Year
GLYC
21.11.2021 - 28.11.2021

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland. Address: 9708 Medical Center Drive, Rockville, MD, United States, 20850

Analytics

WallStreet Target Price

5.5 USD

P/E ratio

Dividend Yield

Current Year

+74 925 USD

Last Year

+1 160 000 USD

Current Quarter

Last Quarter

Current Year

+74 925 USD

Last Year

+1 160 000 USD

Current Quarter

Last Quarter

Key Figures GLYC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -40 131 356 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -46.16 %
PEG Ratio
Return On Equity TTM -80.42 %
Wall Street Target Price 5.5 USD
Revenue TTM
Book Value 0.72 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM 75 000 USD
Earnings Share -0.63 USD
Diluted Eps TTM -0.63 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics GLYC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History GLYC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation GLYC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 555.3967
Price Sales TTM 1154.5992
Enterprise Value EBITDA -1.5219
Price Book MRQ 2.3518

Financials GLYC

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators GLYC

For 52 weeks

1.11 USD 4.16 USD
50 Day MA 1.37 USD
Shares Short Prior Month 893 543
200 Day MA 1.55 USD
Short Ratio 7.48
Shares Short 878 914
Short Percent 1.96 %